Saragoussi Delphine, Touya Maëlys, Haro Josep Maria, Jönsson Bengt, Knapp Martin, Botrel Bastien, Florea Ioana, Loft Henrik, Rive Benoît
Real-World Evidence and Epidemiology, Lundbeck SAS, Issy-les-Moulineaux, France.
Health Economics and Outcomes Research, Lundbeck, Deerfield, IL, US.
Neuropsychiatr Dis Treat. 2017 Aug 9;13:2151-2165. doi: 10.2147/NDT.S136343. eCollection 2017.
The Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder (PERFORM) study has been initiated to better understand the course of a depressive episode and its impact on patient functioning. This analysis aimed to identify sociodemographic and clinical factors associated with failure to achieve remission at month 2 after initiating or switching antidepressant monotherapy and with subsequent relapse at month 6 for patients in remission at month 2.
This was a 2-year observational cohort study in 1,159 outpatients aged 18-65 years with major depressive disorder initiating or undergoing the first switch of antidepressant monotherapy. Factors with <0.20 in univariate logistic regression analyses were combined in a multiple logistic regression model to which backward variable selection was applied (ie, sequential removal of the least significant variable from the model and recomputation of the model until all remaining variables have <0.05).
Baseline factors significantly associated with lower odds of remission at month 2 were body-mass index ≥30 kg/m (OR 0.51), depressive episode >8 weeks (OR 0.51), being in psychotherapy (OR 0.51), sexual dysfunction (OR 0.62), and severity of depression (OR 0.87). Factors significantly associated with relapse at month 6 were male sex (OR 2.47), being married or living as a couple (OR 2.73), residual patient-reported cognitive symptoms at 2 months (OR 1.12 per additional unit of Perceived Deficit Questionnaire-5 score) and residual depressive symptoms at 2 months (OR 1.27 per additional unit of Patient Health Questionnaire-9 score).
Different factors appear to be associated with failure to achieve remission in patients with major depressive disorder and with subsequent relapse in patients who do achieve remission. Patient-reported cognitive dysfunction is an easily measurable and treatable characteristic that may be associated with an increased likelihood of relapse at 6 months in patients who have achieved remission.
为了更好地了解抑郁发作的病程及其对患者功能的影响,启动了与重度抑郁症相关的功能结局前瞻性流行病学研究(PERFORM)。本分析旨在确定在开始或转换抗抑郁药单一疗法后2个月未实现缓解以及在2个月缓解的患者在6个月后复发的社会人口统计学和临床因素。
这是一项为期2年的观察性队列研究,研究对象为1159名年龄在18 - 65岁之间开始或首次转换抗抑郁药单一疗法的重度抑郁症门诊患者。在单因素逻辑回归分析中P<0.20的因素被纳入多因素逻辑回归模型,并应用向后变量选择法(即从模型中依次去除最不显著的变量并重新计算模型,直到所有剩余变量P<0.05)。
与2个月时缓解几率较低显著相关的基线因素包括体重指数≥30kg/m²(比值比[OR]0.51)、抑郁发作>8周(OR 0.51)、接受心理治疗(OR 0.51)、性功能障碍(OR 0.62)以及抑郁严重程度(OR 0.87)。与6个月时复发显著相关的因素包括男性(OR 2.47)、已婚或同居(OR 2.73)、2个月时患者报告的认知症状残留(每增加1个感知缺陷问卷-5得分单位,OR 1.12)以及2个月时抑郁症状残留(每增加1个患者健康问卷-9得分单位,OR 1.27)。
不同因素似乎与重度抑郁症患者未实现缓解以及已实现缓解患者随后的复发有关。患者报告的认知功能障碍是一种易于测量和治疗的特征,可能与已实现缓解的患者在6个月时复发可能性增加有关。